Combined nivolumab and ipilimumab or monotherapy in untreated melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ... New England journal of medicine 373 (1), 23-34, 2015 | 8060 | 2015 |
Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356, 2017 | 3627 | 2017 |
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ... New England journal of medicine 381 (16), 1535-1546, 2019 | 3177 | 2019 |
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ... New England Journal of Medicine 377 (19), 1824-1835, 2017 | 2255 | 2017 |
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial FS Hodi, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CL Cowey, ... The Lancet Oncology 19 (11), 1480-1492, 2018 | 1373 | 2018 |
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial MA Davies, P Saiag, C Robert, JJ Grob, KT Flaherty, A Arance, ... The Lancet Oncology 18 (7), 863-873, 2017 | 729 | 2017 |
Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ... Journal of Clinical Oncology 40 (2), 127-137, 2022 | 691 | 2022 |
Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ... Journal of Clinical Oncology 35 (2), 226-235, 2017 | 577 | 2017 |
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled … PA Ascierto, M Del Vecchio, M Mandalá, H Gogas, AM Arance, S Dalle, ... The Lancet Oncology 21 (11), 1465-1477, 2020 | 458 | 2020 |
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy E Perez-Ruiz, L Minute, I Otano, M Alvarez, MC Ochoa, V Belsue, ... Nature 569 (7756), 428-432, 2019 | 379 | 2019 |
Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial C Lebbé, N Meyer, L Mortier, I Marquez-Rodas, C Robert, P Rutkowski, ... Journal of Clinical Oncology 37 (11), 867-875, 2019 | 327 | 2019 |
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients N Karachaliou, M Gonzalez-Cao, G Crespo, A Drozdowskyj, E Aldeguer, ... Therapeutic advances in medical oncology 10, 1758834017749748, 2018 | 253 | 2018 |
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee U Keilholz, PA Ascierto, R Dummer, C Robert, P Lorigan, A Van Akkooi, ... Annals of oncology 31 (11), 1435-1448, 2020 | 185 | 2020 |
Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials GV Long, JS Weber, J Larkin, V Atkinson, JJ Grob, D Schadendorf, ... JAMA oncology 3 (11), 1511-1519, 2017 | 160 | 2017 |
Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats J Blanco-Rivero, V Cachofeiro, V Lahera, R Aras-Lopez, ... Hypertension 46 (1), 107-112, 2005 | 158 | 2005 |
Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts P Sharma, S López-Tarruella, JA García-Saenz, C Ward, CS Connor, ... Clinical cancer research 23 (3), 649-657, 2017 | 142 | 2017 |
CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ... Journal of Clinical Oncology 39 (15_suppl), 9506-9506, 2021 | 127 | 2021 |
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee O Michielin, A Van Akkooi, P Lorigan, PA Ascierto, R Dummer, C Robert, ... Annals of Oncology 31 (11), 1449-1461, 2020 | 118 | 2020 |
Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel P Sharma, S López-Tarruella, JA García-Saenz, QJ Khan, HL Gómez, ... Clinical Cancer Research 24 (23), 5820-5829, 2018 | 115 | 2018 |
Deregulated miRNAs in Hereditary Breast Cancer Revealed a Role for miR-30c in Regulating KRAS Oncogene M Tanic, K Yanowsky, C Rodriguez-Antona, R Andrés, I Márquez-Rodas, ... PloS one 7 (6), e38847, 2012 | 115 | 2012 |